Preferred Label : SR Mitomycin Intravesical Solution;
NCIt synonyms : Mitomycin Urothelial Gel UGN-102; MMC UG-1 Gel; Intravesical Mitomycin Gel UGN-102; RTGel with Mitomycin C UGN-102; Sustained-release Mitomycin C Hydrogel Formulation UGN-102; Mitomycin Intravesical Solution;
NCIt definition : A sustained-release (SR) reverse thermal (RT) hydrogel formulation containing the
antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity.
Upon intravesical instillation of SR mitomycin intravesical solution , the liquid
converts into gel form and conforms to the bladder wall, allowing MMC to be deposited
locally in the bladder to prevent the excretion of this chemotherapeutic agent via
urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links,
thereby inhibiting DNA synthesis resulting in inhibition of tumor cell proliferation.
Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid
state at cold temperatures, at 4 degrees Celsius, and transition to a water-soluble
gel at body temperature. This allows for increased accumulation of MMC locally in
the upper urinary tract which leads to increased efficacy compared to standard intravesical
delivery of MMC for bladder cancer. Compared to UGN-101, in SR mitomycin intravesical
solution (UGN-102) the strength of MMC is lower.;
Drug name : Vesigel; Zusduri;
Molecule name : UGN-102; UGN 102;
NCI Metathesaurus CUI : CL937895;
Origin ID : C158422;
UMLS CUI : C4764223;
Semantic type(s)
- concept_is_in_subset
- is_component_of_chemotherapy_regimen
